>>> US Gapping up

Gapping up
In reaction earnings/guidance:
  • QTRH +9.8%
M&A news:
  • SNCR +20.4% (remains in discussions with multiple parties regarding potential strategic transaction)
Other news:
  • VBLT +17.2% (announces positive outcome in the third and final DSMC review of Phase 3 GLOBE Trial ABUS +12.7% (signs a share purchase agreement with Roivant Sciences for the sale of $116.4 mln of convertible preferred shares), ITUS +11.8% (completes approx. $3.7 mln common stock offering), TRN +11.6% (favorable court ruling),ECYT +11.3% (completes exclusive worldwide license of PSMA-617 from ABX GmbH), SGEN +7% (FDA has granted ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma Breakthrough Therapy Designation), DVAX +5.8% (considering options for Hepatitis B drug, according to Reuters), MNKD +5.5% (announces that the FDA has approved an update to the Afrezza prescribing info to include new clinical data that was presented at the American Diabetes Association's 76th Scientific Sessions in June 2016), KTOV +5.1% (FDA has filed and NDA for KIT-302, its lead drug candidate, thereby accepting the NDA for a full review), DRRX +4.5% (announced patent purchase agreement with Indivior UK worth $17.5 mln), PSTI +4% (announces a $7.9 mln non-dilutive grant from the European Union's Horizon 2020 program has been awarded to nTRACKg), OPNT +3.3% (Opiant Pharmaceuticals and Titan Pharma (TTNP) announce collaboration ), TTNP +2.9% (Opiant Pharmaceuticals and Titan Pharma (TTNP) announce collaboration ),AIG +1% (Financial Stability Oversight Council rescinded nonbank financial company designation), .
Analyst comments:
  • ZYNE +4.8% (upgraded to Overweight at Cantor Fitzgerald)
  • ALNY +3.8% (upgraded to Buy from Neutral at Goldman)
  • GNRC +2.8% (upgraded to Overweight from Sector Weight at KeyBanc Capital Mkts)
  • STX +2.1% (upgraded to Buy from Hold at Craig Hallum )
  • TRUE +2% (upgraded to Equal-Weight from Underweight at Morgan Stanley)
  • CAVM +1.6% (upgraded to Overweight from Sector Weight at KeyBanc Capital Mkts)
  • ANF +1.5% (upgraded to Hold from Sell at Argus)
  • AKAM +1% (upgraded to Buy from Neutral at Guggenheim )
  • ABBV +0.9% (upgraded to Outperform from Mkt Perform at Leerink Partners)